Avicenna Alliance publication

In silico medicine in Europe


The undersigned, in their capacity as representatives of the VPH Institute, and of the Discipulus, INBIOMEDvision, PHS Foresight, CaSyM, and Avicenna support actions funded by the European Commission in the domain of in silico medicine, as well as the IMI-eTRIKS Consortium agreed to release the following joint statement: The use of information technology in healthcare is progressively expanding from its initial role of managing administrative information into that of support for the provision of care, whether related to prevention, diagnosis, prognosis, or treatment … 

Data Protection Regulation


On 12 March 2014, the European Parliament voted on its position on the new European Union (EU) proposal for a General Data Protection Regulation, which will be now negotiated among the European Parliament, the Council of the European Union and the European Commission [1]. The final text will set the rules under which personal data are to be handled in the EU. It will thus affect many areas of our everyday life, including health and research. The cancer community is deeply concerned about unintended consequences of the current wording of the draft Regulation [2], which may put at stake the survival of retrospective clinical research, biobanking, and populationbased cancer registries in the EU …

Position paper on animal experimentation for scientific purposes


In a context of ageing societies, the general public demands better treatments targeting the most common but also the most rare diseases, chronic and curable conditions, without compromising public health protection and ensuring the efficacy of the new treatments. European and national regulators have been working in the area of safety, quality and efficacy of the new medicinal products. This was reflected in European legislation requiring the conduction of toxicity tests on animals …

Avicenna Alliance news

EU Commission steps up support for personalised medicine

In the past months, the EU has presented several initiatives that jointly have the potential to advance personalised medicine in Europe. Next...

find out more ›

In vivo, in vitro, in silico: Why computer modelling is the next evolution of the healthcare sector

International Conference on In Silico Medicine on 4 September

find out more ›

Cipla brings India perspectives on In Silico to Brussels

New Avicenna Member company Cipla shared some key insights on India’s perspective of In Silico medicine during a visit to Brussels in April....

find out more ›

Show all activites